Testing paradigm for prediction of development-limiting barriers and human drug toxicity

Chemico-Biological Interactions

Volumn 150, Issue 1, 2004, Pages 9-25

  Sasseville, V G ^a   Lane, J H ^a   Kadambi, V J ^a   Bouchard, P ^a   Lee, F W ^a   Balani, S K ^a   Miwa, G T ^a   Smith, P F ^a   Alden, C L ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Clastogenicity; HERG; Idosyncratic; In silico; Mutagenicity; Toxicology

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ATROPINE; BROMFENAC; CAFFEINE; CELECOXIB; CETIRIZINE; CHLORPROMAZINE; CLASTOGEN; DEXAMETHASONE; ERYTHROMYCIN; FIALURIDINE; GELDANOMYCIN; I KAPPA B; INDOMETACIN; LORATADINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHENOBARBITAL; PIOGLITAZONE; SIMVASTATIN; TETRACYCLINE; THEOPHYLLINE; TIABENDAZOLE; TOLCAPONE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; ZILEUTON;

ACCURACY; ARTICLE; ASTHMA; BILE DUCT INJURY; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM; CRYOPRESERVATION; DIGESTIVE SYSTEM INJURY; DRUG COST; DRUG INDUSTRY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; ENZYME METABOLISM; ERYTHROCYTE; GENETIC TOXICOLOGY; HEPATITIS; HUMAN; KIDNEY CANCER; KIDNEY TUBULE DISORDER; LIVER CELL CULTURE; LIVER HYPERTROPHY; LIVER INJURY; LIVER TOXICITY; MUTAGENICITY; NEPHRITIS; PARKINSON DISEASE; PHENOTYPE; PRIMATE; QT PROLONGATION; TECHNOLOGY; TOXICOKINETICS;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; LIVER; MODELS, ANIMAL; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TOXICOLOGY;

PLEURONECTIDAE;

EID: 7444226416     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2004.06.009     Document Type: Article

References (50)

1. J.A. DiMasi, R.W. Hansen, and H.G. Grabowski The price of innovation: new estimates of drug development costs J. Health Econ. 22 2003 151 185
2. J.A. DiMasi The value of improving the productivity of the drug development process: faster times and better decisions Pharmacoeconomics 20 3 2002 1 10
3. C.L. Alden, J.E. Sagartz, P.F. Smith, A.G. Wilson, R.T. Bunch, and D.L. Morris The pathologist and toxicologist in pharmaceutical product discovery Toxicol. Pathol. 27 1999 104 106
4. B.P. Zambrowicz, and A.T. Sands Knockouts model the 100 best-selling drugs - will they model the next 100? Nat. Rev. Drug Discov. 2 2003 38 51
5. B.P. Zambrowicz, C.A. Turner, and A.T. Sands Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry Curr. Opin. Pharmacol. 3 2003 563 570
6. B.H. Horwitz, M.L. Scott, S.R. Cherry, R.T. Bronson, and D. Baltimore Failure of lymphopoiesis after adoptive transfer of NF-kappaB-deficient fetal liver cells Immunity 6 1997 765 772
7. K.N. Khan, C.M. Venturini, R.T. Bunch, J.A. Brassard, A.T. Koki, D.L. Morris, B.F. Trump, T.J. Maziasz, and C.L. Alden Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity Toxicol. Pathol. 5 1998 612 620
8. R.D. Snyder, G.S. Pearl, G. Mandakas, W.N. Choy, F. Goodsaid, and I.Y. Rosenblum Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules Environ. Mol. Mutagen. 43 2004 143 158
9. A.M. Richard Structure-based methods for predicting mutagenicity and carcinogenicity: are we there yet? Mutat. Res. 400 1998 493 507
10. G. Pearl, S. Livingston-Carr, and S. Durham Integration of computational analysis as a sentinel tool in toxicological assessments Curr. Top. Med. Chem. 1 2001 247 255
11. L. He, P.C. Jurs, L.L. Custer, S.K. Durham, and G.M. Pearl Predicting the genotoxicity of polycyclic aromatic compounds from molecular structure with different classifiers Chem. Res. Toxicol. 16 2003 1567 1580
12. B.E. Mattioni, G.W. Kauffman, P.C. Jurs, L.L. Custer, S.K. Durham, and G.M. Pearl Predicting the genotoxicity of secondary and aromatic amines using data subsetting to generate a model ensemble J. Chem. Inf. Comput. Sci. 43 2003 949 963
13. International Conference on Harmonization (ICH) Safety Pharmacology Studies for Human Pharmaceuticals 2000
14. M. Meadows Why drugs get pulled off the market FDA Consumer Mag. 36 2002
15. International Conference on Harmonization (ICH) Safety Pharmacology Studies for Assessing the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals 2002
16. M. Keating, and M. Sangiunetti Molecular and cellular mechanisms of cardiac arrhythmias Cell 104 2001 569 580
17. W.S. Redfern, L. Carlsson, A.S. Davis, W.G. Lynch, I. MacKenzie, S. Palethorpe, P.K.S. Siegl, I. Strang, A.T. Sullivan, R. Wallis, A.J. Camm, and T.G. Hammond Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsades de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovasc. Res. 58 2003 32 45
18. P. Gee, C.H. Sommers, A.S. Melick, X.M. Gidrol, M.D. Todd, R.B. Burris, M.E. Nelson, R.C. Klemm, and E. Zeiger Comparison of responses of base-specific Salmonella tester strains with the traditional strains for identifying mutagens: the results of a validation study Mutat. Res. 30 1998 115 130
19. S. Fluckiger-Isler, M. Baumeister, K. Braun, V. Gervais, N. Hasler-Nguyen, R. Reimann, J. Van Gompel, H.G. Wunderlich, and G. Engelhardt Assessment of the performance of the Ames II assay: a collaborative study with 19 coded compounds Mutat. Res. 558 2004 181 197
20. M. Fenech The in vitro micronucleus technique Mutat. Res. 455 2000 81 95
21. H. Norppa, and G.C. Falck What do human micronuclei contain? Mutagenesis 18 2003 221 233
22. B. Miller, F. Pötter-Locher, A. Seelbach, H. Stopper, D. Utesch, and S. Madle Evaluation of the in vitro micronucleus test as an alternative to the in vitro chromosomal aberration assay: position of the GUM working group on the in vitro micronucleus test Mutat. Res. 410 1998 81 116
23. T. Matsushima, M. Hayashi, A. Matsuoka, M. Ishidate Jr., K.F. Miura, H. Shimizu, Y. Suzuki, K. Morimoto, H. Ogura, K. Mure, K. Koshi, and T. Sofuni Validation study of the in vitro micronucleus test in a Chinese hamster lung cell line (CHL/IU) Mutagenesis 14 1999 569 580
24. J.F. Waring, R.A. Jolly, R. Ciurlionis, P.Y. Lum, J.T. Praestgaard, D.C. Morfitt, B. Buratto, C. Roberts, E. Schadt, and R.G. Ulrich Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles Toxicol. Appl. Pharmacol. 175 2001 28 42
25. J.F. Waring, R. Ciurlionis, R.A. Jolly, M. Heindel, and R.G. Ulrich Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity Toxicol. Lett. 120 2001 359 368
26. F. de Longueville, F.A. Atienzar, L. Marcq, S. Dufrane, S. Evrard, L. Wouters, F. Leroux, V. Bertholet, B. Gerin, R. Whomsley, T. Arnould, J. Remacle, and M. Canning Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes Toxicol. Sci. 75 2003 378 392
27. Committee for Proprietary Medicinal Products (CPMP) Points to Consider: The Assessment of the Potential for QT Prolongation by Non-cardiovascular Medicinal Products 1997
28. S. Irwin Comprehensive observational assessment. Ia. A systematic, quantitative procedure for assessing the behavioral and physiological state of the mouse Psychopharmacologia (Berlin) 13 1968 222 257
29. International Conference on Harmonization (ICH) Genotoxicity: Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals S2A, Guidance for Industry 1996
30. D.J. Waxman P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR and PPAR Arch. Biochem. Biophys. 1999 369
31. M.S. Rao, and J.K. Reddy Peroxisome proliferation and hepatocarcinogenesis Carcinogenesis 8 1987 631 636
32. G.G. Gibson Co-induction of cytochrome P4504A1 and peroxisome proliferation: a causal or casual relationship? Xenobiotica 22 1992 1101 1109
33. J.M. Peters, R.C. Cattley, and F.J. Gonzalez Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643 Carcinogenesis 18 1997 2029 2033
34. D.J. McConn, and Z. Zhao Integrating in vitro kinetic data from compounds exhibiting induction, reversible inhibition and mechanism-based inactivation: in vitro study design Curr. Drug Metab. 5 2004 141 146
35. K.E. Lasser, P.D. Allen, S.J. Woolhandler, D.U. Himmelstein, S.M. Wolfe, and D.H. Bor Timing of new black box warnings and withdrawals for prescription medications J. Am. Med. Assoc. 287 2002 2215 2220
36. K.U. Petersen From toxic precursors to safe drugs: mechanisms and relevance of idiosyncratic drug reactions Arzneimittelforschung 52 2002 423 429
37. J. Feher, A. Vereckei, and G. Lengyel Role of free-radical reactions in liver diseases Acta Physiol. Hung. 80 1992 351 361
38. I.G. McFarlane Pathogenesis of autoimmune hepatitis Biomed. Pharmacother. 53 1999 255 263
39. C. Alden, J. Lin, and P. Smith Predictive technology for avoiding idiosyncratic liver injury Preclinica 2 2003 27 35
40. H. Zimmerman, and K. Ishak Hepatic injury due to drugs, toxins Pathology of the Liver 2002 Churchill Livingstone St. Louis, MO
41. A.P. Li Advancing technologies for accelerated drug development Drug Discov. Today 8 2003 200 202
42. J.P. Buchweitz, P.E. Ganey, S.J. Bursian, and R.A. Roth Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J. Pharmacol. Exp. Ther. 300 2002 460 467
43. Khan The Kidney; Cohen et al., The Lower Urinary Tract; Capen et al., Endocrine; Maranpot, Mastorides, Carcinogenesis Handbook of Toxicologic Pathology 2002 Academic Press London, UK
44. H.C. Pitot, and Y.P. Dragan: Chemical carcinogenesis Casarett and Doull's Toxicology 6th ed. 2001 McGraw-Hill Sydney, Australia
45. C.L. Alden, P.F. Smith, C.E. Piper, and L. Brej A critical appraisal of the value of the mouse cancer bioassay in safety assessment Toxicol. Pathol. 24 1996 722 725
46. B.H. Spargo, and J.R. Taylor The kidney Pathology 1988 Lippincott St. Louis, MO
47. J.W. van der Laan European Society of Toxicology, Annual Meeting London, UK 1999
48. D. Morton, C.L. Alden, A.J. Roth, and T. Usui The Tg rasH2 mouse in cancer hazard identification Toxicol. Pathol. 30 2002 139 146
49. J.B. Pritchard, J.E. French, B.J. Davis, and J.K. Haseman The role of transgenic mouse models in carcinogen identification Environ. Health Perspect. 111 2003 444 454
50. J.W. van der Laan, B.S. Silva-Lima, and D. Snodin Alternative models in carcinogenicity testing - a European perspective Toxicol. Pathol. 30 2002 157 159